



June 30, 2026

To,
Listing Operation Department
BSE Limited
Phiroze Jeejeebhoy Towers,
Dalal Street, Mumbai – 400001
(Scrip Code: 544644)

To,
Listing Compliance Department
National Stock Exchange of India Limited
Exchange Plaza, C-1, Block G, Bandra Kurla
Complex, Bandra (E), Mumbai- 400051
(SYMBOL: CORONA)

Dear Sir / Madam,

Sub.: Intimation under Regulation 30 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 – Commencement of Commercial Production

Pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, we are pleased to inform you that the Company has inaugurated and successfully commenced the commercial production at its EU-GMP approved Women's Hormone manufacturing facility at Bhayla, Ahmedabad.

The Press Release in the matter is enclosed herewith.

This intimation is also being made available on the website of the Company at www.coronaremedies.com

You are requested to take note of the above.

Thanking you.

Yours faithfully,

For CORONA Remedies Limited

Chetna Dharajiya
Company Secretary and Compliance Officer

Encl.: A/a

PRESS RELEASE

CORONA Remedies commercialises India's Most Advanced EU-GMP Approved Women's Hormone Manufacturing Facility

Ahmedabad, June 30, 2026: Reinforcing its long-term commitment to advancing women's healthcare, **CORONA Remedies Limited** today announced the inauguration and commercialisation of its dedicated EU-GMP approved Hormone Manufacturing Facility at Bhayla, Ahmedabad. The facility marks a significant milestone in the Company's journey towards building globally benchmarked pharmaceutical manufacturing capabilities.

The state-of-the-art facility was inaugurated by **Chairman, Dr. K. L. Mehta**, alongside long-serving women employees of the organisation—symbolising CORONA's enduring commitment to women's health and the invaluable contribution of women in shaping the Company's success.

Responding to the Growing Need for Women's Healthcare

As global attention towards women's healthcare continues to grow, driven by greater awareness and diagnosis of hormonal disorders, increasing demand for fertility care and expanding focus on menopause management and hormone replacement therapies, the need for specialised, high-quality pharmaceutical manufacturing has become more critical than ever (as per WHO factsheet on Infertility Nov. 2025). As therapies become increasingly specialised, manufacturing excellence has emerged as a critical pillar alongside clinical innovation.

Hormonal medicines are among the most complex pharmaceutical products to manufacture. Their high potency, sensitive formulations and stringent contamination control requirements demand dedicated facilities equipped with sophisticated technologies, specialised engineering systems and uncompromising regulatory standards.

Recognising this evolving need, CORONA Remedies has established one of India's most advanced dedicated hormone manufacturing facilities, strengthening its capabilities to serve both domestic and international markets.

A Purpose-Built Manufacturing Ecosystem

Unlike conventional pharmaceutical manufacturing plants, dedicated hormone manufacturing requires complete segregation of operations, precision environmental controls, specialised containment technologies and highly trained personnel to ensure safe handling of potent hormone active pharmaceutical ingredients (APIs).

CORONA's integrated manufacturing platform supports multiple dosage forms—including **tablets, soft gel capsules, ointments and gels**—within a single specialised manufacturing ecosystem, enabling the Company to cater to a broad spectrum of women's healthcare therapies.

Spread across **1.0 lakh sq. ft**; the facility has an annual manufacturing capacity of **194 million tablets/capsules** and **1.5 million ointments/gels**. With the commissioning of this facility, CORONA's in-house hormone manufacturing capacity is expected to increase by nearly **20%**.

Advanced Manufacturing Technologies

The facility incorporates next-generation manufacturing technologies and digital process controls to ensure product consistency, precision and operational excellence.

Key capabilities include:

- Fully integrated closed-loop manufacturing systems supported by **21 CFR-compliant equipment** and **Quality by Design (QbD)** principles.
- Advanced gelatin processing systems with precision-controlled agitation and jacketed vessels for accurate temperature management, superior uniformity and formulation consistency.
- Real-time online process monitoring for enhanced batch-to-batch reproducibility and product quality.

Leadership Perspective

Speaking on the occasion, **Mr. Nirav K. Mehta, Founder, Managing Director & CEO, CORONA Remedies Limited** said:

"Women's healthcare continues to be one of the fastest evolving areas of modern medicine. At CORONA, we believe scientific innovation must be complemented by world-class manufacturing capabilities. This dedicated hormone facility represents our commitment to delivering globally benchmarked quality, strengthening India's pharmaceutical manufacturing ecosystem and ensuring women have access to safe, reliable and high-quality hormone therapies."



About CORONA Remedies Limited

Founded in 2004, CORONA Remedies Limited is the India's fastest growing pharmaceutical companies amongst Top 30 Pharmaceutical corporates, engaged in developing, manufacturing, and marketing products across key therapeutic areas including women's healthcare, cardio-diabetes, pain management, and urology. The Company operates WHO GMP / EU GMP-certified manufacturing facilities and maintains strong innovation capabilities through DSIR-approved R&D centres.

Safe Harbour Statement:

Certain statements contained in this document may be statements of future expectations and other forward-looking statements that are based on management's current view and assumptions and involve known and unknown risks and uncertainties that could cause actual results, performance or events to differ materially from those expressed or implied in such statements. None of CORONA Remedies Limited or any of its affiliates, advisors or representatives shall have any liability whatsoever (in negligence or otherwise) for any loss howsoever arising from any use of this document or its content or otherwise arising in connection with this document. This document does not constitute an offer or invitation to purchase or subscribe for any shares and neither it nor any part of it shall form the basis of or be relied upon in connection with any contract or commitment whatsoever.

For further details please contact:

Company	Investor Relations Advisors
CORONA Remedies Limited	Strategic Growth Advisors Pvt Ltd.
CIN: L24231GJ2004PLC044656	CIN: U74140MH2010PTC204285
Ms. Chetna Dharajiya – Company Secretary & Compliance Officer	Mr. Sagar Shroff / Mr. Tanay Shah
Email Id: investor@coronaremedies.com	Email Id: sagar.shroff@sgapl.net / tanay.shah@sgapl.net
	Tel. No.: +91 98205 19303 / +91 98333 91899